Evidence map›Paper›PMID 35611162›Full record

ArticleCellular and molecular bioengineering2022

Minimally-Invasive and Efficient Method to Accurately Fit the Bergman Minimal Model to Diabetes Type 2.

Ana Gabriela Gallardo-Hernández, Marcos A González-Olvera, Medardo Castellanos-Fuentes, Jésica Escobar, Cristina Revilla-Monsalve, Ana Luisa Hernandez-Perez, Ron Leder

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular bioengineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Ana Gabriela Gallardo-HernándezUnidad de Investigación Médica en Enfermedades Metabólicas CMNSXII, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Marcos A González-OlveraUniversidad Autónoma de la Ciudad de México, Mexico City, Mexico.ORCID 0000-0001-8174-4391
Medardo Castellanos-FuentesUnidad Médica de Alta Especialidad en Cardiología CMNSXII, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Jésica EscobarUnidad Zacatenco, IPN, Escuela Superior de Ingeniería Mecánica y Eléctrica, Mexico City, Mexico.
Cristina Revilla-MonsalveUnidad de Investigación Médica en Enfermedades Metabólicas CMNSXII, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Ana Luisa Hernandez-PerezDepartamento de Anestesiología, Hospital ABC, Mexico City, Mexico.
Ron LederEngineering in Medicine and Biology IEEE, Mexico City, Mexico.
Mexican Social Security Institute · MXCentro Médico ABC · MXInstituto Politécnico Nacional · MXUniversidad Autónoma de la Ciudad de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Diabetes mellitus is a global burden that is expected to grow Methods: Twenty experiments were performed with Sprague-Dawley rats with streptozotocin induced experimental diabetes in which the insulin-glucose response curve was recorded over 60-100 min using only an insulin pump and a percutaneous glucose sensor. The information was used to fit the five-parameter Bergman Minimal Model to the experimental results using a genetic algorithm with a root-mean-squared optimization rule. Results: The Bergman Minimal Model parameters were estimated with high accuracy, low prediction bias, and low average root-mean-squared error of 15.27 mg/dl glucose. Conclusions: This study demonstrates a simple method to accurately parameterize the Bergman Minimal Model. We used Sprague-Dawley rats since their physiology is close to that of humans. The parameters can be used to objectively characterize the physiological severity of diabetes. In this way, planned treatments can compensate for natural variations of conditions both inter and intra patients. Changes in parameters indicate the patient's diabetic condition using values of glucose effectiveness (

Indexed as

Genetic algorithmGlucose effectivenessIndividualized diabetes treatmentInsulin sensitivity

Identifiers

PMID35611162
PMCPMC9124285
OpenAlexW4210773287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.